PubMed
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging (FOXO4-DRI)
Baar MP, Brandt RMC, Putavet DA, et al. Cell. 2017
Compare
FOXO4-DRI vs Liraglutide
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
FOXO4-DRI
28 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 97% · Mixed 3% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
178
Energy
178
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 1 to ≥ 2 mg (open-ended top bucket)
1–2 mg
58
2+ mg
120
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 88% said they felt similar to their last entry, 12% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 194 days · Based on 26 repeat reporters
Liraglutide
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
6
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 1 to ≥ 2 mg (open-ended top bucket)
1–2 mg
2
2+ mg
4
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Sources (9)
Published sources linked on the FOXO4-DRI and Liraglutide wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
Born E, Lipskaia L, Breau M, et al. Circulation. 2023
- Wiki study page →Source
PubMed
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Baar MP, Brandt RMC, Putavet DA, et al. Cell. 2017
- Wiki study page →Source
FDA Drug Label
SAXENDA (liraglutide) injection — Prescribing Information
Novo Nordisk. FDA Drug Label. 2014
- Wiki study page →Source
FDA Drug Label
VICTOZA (liraglutide) injection — Prescribing Information
Novo Nordisk. FDA Drug Label. 2010
- Wiki study page →Source
PubMed
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER trial)
Marso SP, Daniels GH, Brown-Frandsen K, et al. N Engl J Med. 2016
- Wiki study page →Source
PubMed
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE)
Pi-Sunyer X, Astrup A, Fujioka K, et al. N Engl J Med. 2015
- Wiki study page →Source
PubMed
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial
Rubino DM, Greenway FL, Khalid U, et al. JAMA. 2022
- Wiki study page →Source
PubMed
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
Garvey WT, Birkenfeld AL, Dicker D, et al. Diabetes care. 2020